{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-197821","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.935414+00:00","generated_at":"2026-05-31T10:36:49.809843+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory","bullets":["Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.","Paul Thomas appointed Chair of the Board, effective August 9, 2024; he joined the Board in 2020.","Dale receives $765k base salary, 100% target bonus, and 600,000 PSUs tied to stock price goals and Avance Nerve Graft BLA approval.","Dale has 30+ years med device experience, most recently President of structural heart at Abbott (NYSE: ABT).","Zaderej remains in advisory role for nine months under a previously disclosed Transition and Separation Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-197821","json":"https://secwatch.observer/filing/0001193125-24-197821.json","markdown":"https://secwatch.observer/filing/0001193125-24-197821.md","text":"https://secwatch.observer/filing/0001193125-24-197821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000119312524197821/0001193125-24-197821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000119312524197821/d831362d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:36:49.809843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f4213d3c8","claim":"Michael Dale was appointed as Chief Executive Officer, President, and Director at Axogen, Inc..","evidence_excerpt":"On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000119312524197821/0001193125-24-197821-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, President, and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}